

DAFTAR PUSTAKA

1. Albright et al. Disseminata , Areas of Pigmentation and Endocrine. N Engl J Med. 1937;216(17):721–46.
2. Wiedemann HR, Kunze J GF. Clinical syndromes. Edisi keti. Mosby-Wolfe; 1997. h. 360-1.
3. Dumitrescu CE, Collins MT. McCune-Albright syndrome. Orphanet J Rare Dis. 2008;3(1):1–12.
4. Collins MT, Singer FR, Eugster E. McCune-Albright syndrome and the extraskeletal manifestations of fibrous dysplasia. Orphanet J Rare Dis. 2012;7(SUPPL. 1):1–14.
5. Chapurlat RD, Orcel P. Fibrous dysplasia of bone and McCune-Albright syndrome. Best Pract Res Clin Rheumatol. 2008;22(1):55–69.
6. Eugster EA, Rubin SD, Reiter EO, Plourde P, Jou HC, Pescovitz OH. Tamoxifen treatment for precocious puberty in McCune-Albright syndrome: A multicenter trial. J Pediatr. 2003;143(1):60–6.
7. Collins MT, Sarlis NJ, Merino MJ, Monroe J, Crawford SE, Krakoff JA, et al. Thyroid carcinoma in the McCune-Albright syndrome: Contributory role of activating Gs α mutations. J Clin Endocrinol Metab. 2003;88(9):4413–7.
8. Ismail H, Ness K. Evaluation of short stature in children. Pediatr Ann. 2013;42(11):217–22.
9. Schwindinger WF, Francomano CA, Levine MA. Identification of a mutation in the gene encoding the α subunit of the stimulatory G protein of adenylyl cyclase in McCune-Albright syndrome. Proc Natl Acad Sci U S A. 1992;89(11):5152–6.
10. Lumbroso S, Paris F, Sultan C. Activating Gs α Mutations: Analysis of 113 Patients with Signs of McCune-Albright Syndrome - A European Collaborative Study. J Clin Endocrinol Metab. 2004;89(5):2107–13.
11. Cantas-Orsdemir S, Eugster EA. Update on central precocious puberty: from etiologies to outcomes. Expert Rev Endocrinol Metab [Internet]. 2019;14(2):123–30. Available from: <https://doi.org/10.1080/17446651.2019.1575726>
12. Lee PA, Neely EK, Fuqua J, Yang D, Larsen LM, Mattia-Goldberg C, et al. Efficacy of Leuprolide Acetate 1-Month Depot for Central Precocious Puberty (CPP): Growth Outcomes During a Prospective, Longitudinal Study. Int J Pediatr Endocrinol. 2011;2011(1):1–9.

13. Ikatan Dokter Anak Indonesia. Perawakan Pendek pada Anak dan Remaja di Indonesia. Pandu Prakt Klin Ikat Dr Anak Indones. 2017;1–19.
14. Lemon SM, Walker CM. HHS Public Access. *Physiol Behav*. 2019;26:1423–44.
15. Weir K. The risks of earlier puberty. *Am Psychological Assoc*. 2016;47(No(Monitor on Psychology)):40.
16. Eugster EA. Treatment of central precocious puberty. *J Endocr Soc*. 2019;3(5):965–72.
17. McCUNE D. Osteodystrophia Fibrosa: Report of a Case in Which the Condition Was Combined With Precocious Puberty, Pathologic Pigmentation of the Skin and Hyperthyroidism, With a Review of the Literature. *Am J Dis Child*. 1937;54(4):806–48.
18. Haghighatafshar M, Karami F, Saghari M, Beiki D. McCune-Albright syndrome : Report of a case McCune-Albright Syndrome : Report of a Case. 2010;(May 2015):1–6.
19. Schoelwer M, Eugster EA. Treatment of peripheral precocious puberty. *Endocr Dev*. 2016;29:230–9.
20. Klein DJ, Thorn CF, Desta Z, Flockhart DA, Altman RB, Klein TE. PharmGKB summary: Tamoxifen pathway, pharmacokinetics. *Pharmacogenet Genomics*. 2013;23(11):643–7.
21. Lahlou N, Carel JC, Chaussain JL, Roger M. Pharmacokinetics and pharmacodynamics of GnRH agonists: Clinical implications in pediatrics. *J Pediatr Endocrinol Metab*. 2000;13(SUPPL. 1):723–37.
22. Carel JC, Lahlou N, Roger M, Chaussain JL. Precocious puberty and statural growth. *Hum Reprod Update*. 2004;10(2):135–47.
23. Yoo JJ, Lim YS, Kim MS, Lee B, Kim BY, Kim Z, et al. Risk of fatty liver after long-term use of tamoxifen in patients with breast cancer. *PLoS One [Internet]*. 2020;15(7 July):1–16. Available from: <http://dx.doi.org/10.1371/journal.pone.0236506>
24. Guaraldi F, Beccuti G, Gori D, Ghizzoni L. Long-term outcomes of the treatment of central precocious puberty. *Eur J Endocrinol*. 2016;174(3):R79–87.
25. Faizi M, Artati RD, Pulungan AB. Diagnosis dan Tata Laksana Pubertas Prekoks Sentral. Badan Penerbit Ikat Dr Anak Indones. 2017;1–15.
26. Muir A. Precocious puberty. *Pediatr Rev*. 2006;27(10):373–81.
27. Emons G, Mustea A, Tempfer C. Tamoxifen and endometrial cancer: A janus-headed drug. *Cancers (Basel)*. 2020;12(9):1–11.
28. Chang HT, Pan HJ, Lee CH. Prevention of Tamoxifen-related Nonalcoholic Fatty Liver Disease in Breast Cancer Patients. *Clin Breast Cancer [Internet]*. 2018;18(4):e677–85. Available from: <https://doi.org/10.1016/j.clbc.2017.11.010>



29. Mastorakos G, Mitsiades NS, Doufas AG, Koutras DA. Hyperthyroidism in McCune-Albright syndrome with a review of thyroid abnormalities sixty years after the first report. *Thyroid*. 1997;7(3):433–9.
30. Bhimma R, Coovadia HM, Adhikari M. Nephrotic syndrome in South African children: Changing perspectives over 20 years. *Pediatr Nephrol*. 1997;11(4):429–34.
31. Turan, Ahi P. 1 ; Akca SO 2. The Quality of Life of Children with Precocious Puberty and Healthy Children in Turkey. *Am J Heal Behav*. 2021;45(1):62–70.
32. De Buff Passone CG, Kuperman H, Cabral De Menezes-Filho H, Spassapan Oliveira Esteves L, Lana Obata Giroto R, Damiani D. Tamoxifen improves final height prediction in girls with mccune-albright syndrome: A long follow-up. *Horm Res Paediatr*. 2015;84(3):184–9.